Results 221 to 230 of about 20,867 (266)
Some of the next articles are maybe not open access.
Scandinavian Journal of Clinical and Laboratory Investigation, 2001
Incretin hormones are insulinotropic hormones from the intestinal mucosa, which after being released in response to ingestion of a meal, enhance insulin secretion in excess of that elicited by the absorbed nutrients (glucose. amino acids etc) themselves.
Holst, J.J., Orskov, C.
openaire +2 more sources
Incretin hormones are insulinotropic hormones from the intestinal mucosa, which after being released in response to ingestion of a meal, enhance insulin secretion in excess of that elicited by the absorbed nutrients (glucose. amino acids etc) themselves.
Holst, J.J., Orskov, C.
openaire +2 more sources
Incretin Pharmacology: A Review of the Incretin Effect and Current Incretin-Based Therapies
Cardiovascular & Hematological Agents in Medicinal Chemistry, 2012Given the demonstrated importance of the incretin effect on the prandial insulin response, augmentation of the incretin effect in people with type 2 diabetes is an important pharmacological approach to glycemic management. In recent years, the use of incretin-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors, has increased ...
openaire +2 more sources
Orvosi Hetilap, 2011
The discovery of incretins − glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrop peptide (GIP) −, clarification of their physiological properties as well as therapeutic application of incretin-based blood glucose lowering drugs opened new perspectives in the medical management of type 2 diabetes.
openaire +2 more sources
The discovery of incretins − glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrop peptide (GIP) −, clarification of their physiological properties as well as therapeutic application of incretin-based blood glucose lowering drugs opened new perspectives in the medical management of type 2 diabetes.
openaire +2 more sources
GLUCOREGULATORY ACTIONS OF INCRETINS/ANTI-INCRETINS
2023Diabetes mellitus (DM) is a chronic debilitating and non-communicable disease characterized by chronic hyperglycemia and resulting from a defect in insulin secretion, insulin action, or both. Apart from these, defective actions of the gastrointestinal (GI) incretin hormones: glucagon-like peptide–1 (GLP-1) and glucose-dependent insulinotropic ...
openaire +1 more source
Incretins and risk of neoplasia
BMJ, 2013An association exists but causality has not yet been proved Incretin based treatment for type 2 diabetes improves hyperglycaemia without causing weight gain and is increasingly being used worldwide. Concerns have been raised about long term safety, as reported by Cohen,1 especially the risk of pancreatitis and pancreatic cancers—both adenocarcinoma ...
Thorvardur R, Halfdanarson +1 more
openaire +2 more sources
Pleiotropic effects of incretins and antidiabetics with incretine mechanism
Orvosi Hetilap, 2013Discovery of physiological and pharmacological characteristics of incretins (glucagon-like peptide-1 and glucose-dependent insulinotrop polypeptide), and the introduction of various products of those into the clinical practice has fundamentally changed blood glucose lowering therapy in type 2 diabetes.
openaire +2 more sources
Hormone and Metabolic Research, 2004
Incretins are hormones released by nutrients from the GI tract. They amplify glucose-induced insulin release. By raising circulating incretin levels, oral glucose provokes a higher insulin response than that resulting from intravenous glucose. The two most important incretin hormones are glucose-dependent insulinotropic polypeptide (GIP) and glucagon ...
S, Efendic, N, Portwood
openaire +2 more sources
Incretins are hormones released by nutrients from the GI tract. They amplify glucose-induced insulin release. By raising circulating incretin levels, oral glucose provokes a higher insulin response than that resulting from intravenous glucose. The two most important incretin hormones are glucose-dependent insulinotropic polypeptide (GIP) and glucagon ...
S, Efendic, N, Portwood
openaire +2 more sources
Incretins and Lipid Metabolism
Current Medicinal Chemistry, 2018Background: Recent findings indicate that incretin hormones and incretin-based therapies may affect the metabolism of lipoproteins, although the corresponding mechanisms are not clearly defined. Objective: To summarize the available data on the mechanisms linking incretins with the characteristics of serum lipoproteins and discuss the clinical ...
Vasilis, Tsimihodimos, Moses, Elisaf
openaire +2 more sources
Cardiovascular benefits of incretins
BMJ, 2013Cohen and colleagues make no mention of the evidence that treatment of type 2 diabetes with increasingly larger doses of sulfonylureas and insulin is not without serious risk from hypoglycaemia, weight gain, and possibly increased cardiovascular risk.1 A balanced account of this is needed in any review of incretins.
Anthony H, Barnett, Paul, O'Hare
openaire +2 more sources
[Incretin and incretin-based therapies].
Nihon rinsho. Japanese journal of clinical medicine, 2010GIP and GLP-1 are major incretins and secreted from K-cell and L-cell in response to meal ingestion, respectively. GIP and GLP-1 potentiate glucose-induced insulin secretion by binding GIP receptor and GLP-1 receptor, respectively, on pancreatic beta-cell and increasing intracellular cAMP concentration (incretin effect). GIP receptor and GLP-1 receptor
Norio, Harada, Nobuya, Inagaki
openaire +1 more source